Previous Article | Next Article ![]()
Infection and Immunity, November 2001, p. 7169-7172, Vol. 69, No. 11
Department of Microbiology, University of
Minnesota Medical School, Minneapolis, Minnesota 55455
Received 16 March 2001/Returned for modification 15 May
2001/Accepted 17 July 2001
Host susceptibility to lipopolysaccharide (LPS) is correlated with
the levels of circulating tumor necrosis factor alpha (TNF- The susceptibility of different
animal species to the toxicity of lipopolysaccharide (LPS) is highly
variable. Although the mechanisms underlying this variability are not
well understood, host susceptibility to LPS appears to be correlated
with levels of circulating tumor necrosis factor alpha (TNF- Alternatively, species resistant to LPS may express a relative
resistance to the lethal effects of TNF- TSST-1 and serovar Typhimurium LPS were prepared as described elsewhere
(4, 22) and administered intraperitoneally (i.p.) to
BALB/c-AnNCr mice (National Cancer Institute, Frederick, Md.) or
intravenously (i.v.) to Dutch belted rabbits (Birchwood Farms, Redwing,
Minn.). Serum samples were collected from mice and rabbits, stored at
We have previously published the time course of TNF- Since the effect of TSST-1 on LPS-induced TNF-
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.11.7169-7172.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Comparative Analysis of Lipopolysaccharide-Induced
Tumor Necrosis Factor Alpha Activity in Serum and Lethality in Mice
and Rabbits Pretreated with the Staphylococcal Superantigen Toxic Shock
Syndrome Toxin 1
![]()
ABSTRACT
Top
Abstract
Text
References
) that
develop in response to circulating LPS. Mice are resistant, relative to
rabbits, to the lethal effects of LPS. This study indicates that mice
and rabbits are equally sensitive to the lethal effects of circulating
TNF-
but that mice are more resistant than rabbits to the induction
of circulating TNF-
by LPS.
![]()
TEXT
Top
Abstract
Text
References
) that
develop in response to LPS. For example, humans are exquisitely
sensitive to LPS, with the lethal dose of LPS in humans being as low as 1 to 2 µg (18). Injection of 4 ng of
Escherichia coli LPS/kg into human volunteers caused a mean
peak circulating TNF-
concentration of 240 pg/ml (14).
Though not as susceptible to LPS as humans, rabbits are more
susceptible to LPS than mice (15). Outbred New Zealand
rabbits challenged with a fatal dose of 10 µg of Salmonella enterica serovar Minnesota Re595 LPS/kg developed a mean peak circulating TNF-
concentration of 25.2 ng/ml (13). In
contrast, C57BL/6 mice challenged with a higher but nonlethal
50-µg/kg dose of S. enterica serovar Enteritidis LPS
developed a peak circulating TNF-
concentration of only 3 ng/ml
(17). These data suggest that the TNF-
-inducing
potential of LPS is proportionally greater in species with greater
sensitivity to LPS. TNF-
is a critical mediator of LPS-induced shock
in experimental animals (2, 13), and administration of
purified recombinant TNF-
to rats or dogs reproduced much of the
vascular instability caused by injection of LPS (20, 21).
Resistance to the TNF-
-inducing effects of LPS may therefore explain
species-specific responsiveness to LPS.
itself. It has even been
proposed that the vascular physiology of mice is fundamentally different from that of humans (1). To address these
possibilities, we directly compared the LPS-induced levels of TNF-
in serum associated with lethality in mice to those measured in
rabbits. The 50% lethal dose (LD50) of S. enterica serovar Typhimurium LPS in BALB/c-AnNCr mice (2 mg/kg)
and Dutch belted rabbits (500 µg/kg) have previously been reported
(6, 11). To reduce the dose of LPS required for lethality
in each species, we induced LPS hypersensitivity in each species by
pretreating animals with the superantigen toxic shock syndrome toxin 1 (TSST-1). TSST-1 greatly potentiates LPS-induced serum TNF-
responses in mice (6, 9), and TNF-
was shown to be a
required mediator of lethality in mice with superantigen-induced
hypersensitivity to LPS (19).
70°C, and later assayed for cytolytic activity on WEHI clone 13 target cells (7) according to a recently described protocol (6). By convention, 1 U of TNF activity per ml is defined as the concentration of TNF that causes 50% lysis of target cells. The concentration of purified murine recombinant TNF-
(R & D
Systems, Minneapolis, Minn.) that typically caused 50% lysis of WEHI
clone 13 cells was 1.0 pg/ml. Monoclonal antibodies to rabbit TNF-
(Pharmingen, San Diego, Calif.) neutralized >90% of the cytolytic
activity in rabbit serum collected 1 h after injection of LPS
(10.0 µg/kg [i.v.]; data not shown). These antibodies were equally
effective in neutralizing the cytolytic activity in rabbit serum
collected 1 h after the sequential injection of LPS (10.0 µg/kg
[i.v.]) and TSST-1 (10 ng/kg [i.v.]), with the dose of TSST-1 given
12 h prior to challenge with LPS (data not shown). The serum
cytolytic activity measured in the following experiments was therefore
attributed to TNF-
. The lower limit of detection of TNF-
in serum
was 20 U/ml. Statistical analyses were performed on
log10-transformed scores of measured TNF-
values, and samples containing <20 U of TNF-
/ml were arbitrarily
assigned a value of 10 U/ml prior to log transformation. Student's
t test for samples with unequal variances was used to
determine the significance of differences between independent means.
LD50 statistics were calculated as described
elsewhere (16).
in serum
induced by a lethal dose of LPS (400 µg/kg) in BALB/c-AnNCr mice
primed for 12 h with 200 µg of TSST-1/kg (6). Peak
levels of TNF-
in serum were measured at 1 to 2 h postinjection
of LPS in this model, and the maximum enhancement effect of TSST-1 on LPS-induced TNF-
was measured at 2 h postinjection of LPS. At this time point, LPS-induced TNF-
levels in serum were ca.
1,000-fold higher in mice primed with TSST-1 compared to unprimed mice.
has not been examined
in the rabbit, we determined the time course and dose response of
LPS-induced TNF-
activity in serum in rabbits primed with TSST-1 for
12 h. When the challenge dose of LPS was held constant at 10 µg/kg, the LD50 for the priming dose of TSST-1 was ca. 10 ng/kg (Table 1). Figure
1 shows the time course of TNF-
in
serum that developed in rabbits primed with 10 ng of TSST-1/kg and then
challenged with 10 µg of LPS/kg 12 h later. A significant
difference between LPS-induced TNF-
levels in serum in unprimed and
TSST-1-primed rabbits was measured at each of the time points tested
(P
0.05). As was observed in BALB/c-AnNCr mice
(6), peak LPS-induced levels of TNF-
in serum were
measured at 1 to 2 h postinjection of LPS. However, in contrast to
BALB/c-AnNCr mice, the enhancement effect of TSST-1 on the LPS-induced
TNF-
response in serum was greatest at 4 h after injection of
LPS in rabbits. At this time point, LPS-induced TNF-
levels in serum were ca. 1,500-fold higher in rabbits primed with TSST-1 compared to
unprimed rabbits (Fig. 1). Control rabbits injected with 5 µg/kg
(i.v.) of TSST-1 alone, followed by phosphate-buffered saline (PBS)
12 h later, did not develop detectable TNF-
levels in serum.
TABLE 1.
Dose response of LPS-induced lethality and TNF-
activity in serum in rabbits primed with TSST-1

View larger version (21K):
[in a new window]
FIG. 1.
Time course of LPS-induced TNF-
in serum in Dutch
belted rabbits primed with TSST-1. Groups of three rabbits were
injected with 10.0 ng (i.v.) of TSST-1 (primed)/kg or an equivalent
volume of PBS (unprimed). All rabbits were injected with LPS (10 µg/kg [i.v.]) 12 h later. Control rabbits injected with 5 µg
of TSST-1 and PBS/kg 12 h later did not develop detectable levels
of TNF-
. (*, P
0.05).
As shown in Table 1, the peak level of TNF-
in serum induced by LPS
in rabbits given the LD50 of TSST-1 and LPS (10 ng of TSST-1/kg plus 10 µg of LPS/kg) was 12-fold higher than that
measured in unprimed rabbits treated with LPS alone. Higher priming
doses of TSST-1 enhanced peak LPS-induced TNF-
levels in serum by as much as 242-fold.
To determine if lethality was associated with equivalent peak levels of
LPS-induced TNF-
activity in serum in mice and rabbits, we directly
compared the peak TNF-
activity in serum induced by TSST-1 and LPS
in BALB/c-AnNCr mice to that measured in Dutch belted rabbits. Peak
TNF-
activity was measured in serum specimens retained from
previously conducted time course experiments with BALB/c-AnNCr mice
(6) and Dutch belted rabbits (Fig. 1). Serum samples were
collected 2 h after injection of LPS from mice (n = 3) that received 200 µg of TSST-1/kg, followed 12 h later by 400 µg of LPS/kg, or from rabbits (n = 3) that
received 10 ng of TSST-1/kg, followed 12 h later by 10 µg of
LPS/kg. The combined doses of TSST-1 and LPS injected were the minimum
doses that consistently caused 100 or 50% fatality rates in mice or
rabbits, respectively. Serum samples from each species were tested for
TNF-
activity in the same assay. When measured in the bioassay for
TNF-
, the specific activity of murine recombinant TNF-
(R & D
systems) was 2.56 × 108 U/mg, while that of
rabbit TNF-
in conditioned medium (Pharmingen) was 3.72 × 108 U/mg. These specific activities were used to
calculate corrected TNF-
scores from measured levels of TNF-
activity in serum. Corrected TNF-
values are expressed as levels of
circulating TNF-
protein (in nanograms/milliliter).
Figure 2 shows the peak levels of
circulating TNF-
activity induced by the sequential injection of
TSST-1 and LPS into mice and rabbits. The peak levels of TNF-
activity (mean ± the standard error of the mean) in serum
measured in mice and rabbits were 874,000 ± 218,000 and
546,000 ± 109,000 U/ml, respectively. The difference between
these uncorrected means did not reach statistical significance
(P = 0.23). However, when measured TNF-
levels were corrected based on the specific activities of murine and rabbit TNF-
in the bioassay, the mean peak level of circulating TNF-
in mice
(3,410 ng/ml) was nearly twice that measured in rabbits (1,470 ng/ml).
Although the difference between these corrected means approached
statistical significance (P = 0.06), the biological relevance of this difference must be interpreted with caution. If the
fatality rates observed for each species were equivalent, then the
finding of a greater peak TNF-
response in mice compared to rabbits
would lend support to the notion that mice are less sensitive than
rabbits to the lethal effects of circulating TNF-
. However, the
doses of TSST-1 and LPS injected were the minimum required to cause
fatality rates of 100 and 50% in mice and rabbits, respectively. If
both the mice and the rabbits had been injected with an
LD50 of TSST-1 and LPS, the peak levels of
TNF-
measured in the sera of each of the species would probably have
been even more equivalent. In view of the observed fatality
rates and statistically equivalent peak TNF-
levels in serum in mice
and rabbits, we concluded that lethality developed at approximately the
same peak circulating level of TNF-
in both species.
|
Also shown in Fig. 2 are the fractions of circulating TNF-
attributable to LPS alone, which were determined in our previous time
course studies with the same animals. These fractions reveal that LPS
is a much more potent inducer of serum TNF-
in rabbits compared to
mice. Fortyfold less LPS was given to rabbits compared to mice, but
this dose induced ca. fiftyfold more serum TNF-
in rabbits relative
to mice. A much greater priming dose of TSST-1 was therefore required
to raise peak levels of TNF-
in serum in mice to levels associated
with lethality. Finally, since the half-life of circulating TNF-
is
short in both mice (t1/2 = 6 min
[3]) and rabbits (biphasic
t1/2 = 0.5, 11 min
[13]), the greater TNF-
-inducing potency of LPS in
rabbits probably reflects greater production rather than slower
clearance of TNF-
.
Of particular relevance to this study are previous experiments in which
purified human TNF-
was administered to mice, rats, or dogs
(5, 20, 21). These experiments not only demonstrated that
TNF-
was a lethal cytokine but also revealed that mice were relatively resistant to the lethal effects of human TNF-
. Whereas the lethal dose of human TNF-
in mice was in excess of 1 mg/kg, doses of as low as 10 µg of murine TNF-
/kg caused death in mice (5). The resistance of mice to human TNF-
has been
attributed to the failure of human TNF-
to engage the murine p75
receptor for TNF (10, 12), and this limited
cross-reactivity of TNF-
in vivo has undoubtedly complicated
assessments of TNF-
sensitivity across species. By showing that
lethality develops in mice and rabbits at comparable circulating levels
of homologous TNF-
, our data predict that the lethal dose of
homologous TNF-
in rabbits would be close to that measured in mice
(ca. 10 µg/kg).
In conclusion, this evidence challenges the notion that the vascular
responses of mice to TNF-
or LPS are fundamentally different from
species more susceptible to LPS (1). Instead, it favors a
theory for murine resistance to LPS that is centered on species differences in the molecules required for potent cytokine induction by
LPS. Murine resistance to shock induced by staphylococcal or streptococcal superantigens may likewise be due to a relative impairment in the ability of these toxins to induce cytokine release from murine immune cells. Transgenic mice expressing human CD14 or
HLA-DQ6 exhibited significant increases in susceptibility to LPS or
staphylococcal enterotoxin B (8, 23), respectively, thereby linking species variability in LPS or superantigen sensitivity to minor species differences in the cellular receptors for these toxins.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by USPHS research grant AI22159 from the National Institute of Allergy and Infectious Diseases.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, University of Minnesota Medical School, 420 Delaware St., SE, Minneapolis, MN 55455-0312. Phone: (612) 624-9471. Fax: (612) 626-0623. E-mail: pats{at}lenti.med.umn.edu.
Editor: J. D. Clements
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
American College of Chest Physicians.
1997.
Executive summary. From bench to the bedside: the future of sepsis research. National Institute of Allergy and Infectious Disease and National Heart, Lung, and Blood Institute Workshop.
Chest
111:744-753 |
| 2. |
Beutler, B.,
I. W. Milsark, and A. C. Cerami.
1985.
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.
Science
229:869-871 |
| 3. | Beutler, B. A., I. W. Milsark, and A. Cerami. 1985. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J. Immunol. 135:3972-3977[Abstract]. |
| 4. | Blomster-Hautamaa, D. A., and P. M. Schlievert. 1988. Purification of toxic shock syndrome toxin-1. Methods Enzymol. 165:37-43[Medline]. |
| 5. | Brouckaert, P. G., B. Everaerdt, C. Libert, N. Takahashi, and W. Fiers. 1989. Species specificity and involvement of other cytokines in endotoxic shock action of recombinant tumour necrosis factor in mice. Agents Actions 26:196-198[CrossRef][Medline]. |
| 6. |
Dinges, M. M., and P. M. Schlievert.
2001.
Role of T cells and gamma-interferon during induction of hypersensitivity to lipopolysaccharide by toxic shock syndrome toxin 1 in mice.
Infect. Immun.
69:1256-1264 |
| 7. | Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99-105[CrossRef][Medline]. |
| 8. |
Ferrero, E.,
D. Jiao,
B. Z. Tsuberi,
L. Tesio,
G. W. Rong,
A. Haziot, and S. M. Goyert.
1993.
Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide.
Proc. Natl. Acad. Sci. USA
90:2380-2384 |
| 9. |
Henne, E.,
W. H. Campbell, and E. Carlson.
1991.
Toxic shock syndrome toxin 1 enhances synthesis of endotoxin-induced tumor necrosis factor in mice.
Infect. Immun.
59:2929-2933 |
| 10. |
Kramer, S. M.,
B. B. Aggarwal,
T. E. Eessalu,
S. M. McCabe,
B. L. Ferraiolo,
I. S. Figari, and M. A. Palladino, Jr.
1988.
Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha.
Cancer Res.
48:920-925 |
| 11. |
Lee, P. K.,
J. R. Deringer,
B. N. Kreiswirth,
R. P. Novick, and P. M. Schlievert.
1991.
Fluid replacement and polymyxin B protection of rabbits challenged subcutaneously with toxic shock syndrome toxins.
Infect. Immun.
59:879-884 |
| 12. |
Lewis, M.,
L. A. Tartaglia,
A. Lee,
G. L. Bennett,
G. C. Rice,
G. H. Wong,
E. Y. Chen, and D. V. Goeddel.
1991.
Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific.
Proc. Natl. Acad. Sci. USA
88:2830-2834 |
| 13. | Mathison, J. C., E. Wolfson, and R. J. Ulevitch. 1988. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J. Clin. Investig. 81:1925-1937. |
| 14. | Michie, H. R., K. R. Manogue, D. R. Spriggs, A. Revhaug, S. O'Dwyer, C. A. Dinarello, A. Cerami, S. M. Wolff, and D. W. Wilmore. 1988. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318:1481-1486[Abstract]. |
| 15. | Redl, H., S. Bahrami, G. Schlag, and D. L. Traber. 1993. Clinical detection of LPS and animal models of endotoxemia. Immunobiology 187:330-345[Medline]. |
| 16. | Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27:493-497. |
| 17. | Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802[CrossRef][Medline]. |
| 18. | Sauter, C., and C. Wolfensberger. 1980. Interferon in human serum after injection of endotoxin. Lancet ii:852-853. |
| 19. |
Stiles, B. G.,
Y. G. Campbell,
R. M. Castle, and S. A. Grove.
1999.
Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1.
Infect. Immun.
67:1521-1525 |
| 20. |
Tracey, K. J.,
B. Beutler,
S. F. Lowry,
J. Merryweather,
S. Wolpe,
I. W. Milsark,
R. J. Hariri,
T. J. D. Fahey,
A. Zentella,
J. D. Albert, et al.
1986.
Shock and tissue injury induced by recombinant human cachectin.
Science
234:470-474 |
| 21. | Tracey, K. J., S. F. Lowry, T. J. D. Fahey, J. D. Albert, Y. Fong, D. Hesse, B. Beutler, K. R. Manogue, S. Calvano, H. Wei, et al. 1987. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg. Gynecol. Obstet. 164:415-422[Medline]. |
| 22. | Westphal, O., O. Luderitz, and F. Blister. 1952. Uber die Extraktion von Bacterien mit Phenol/Wasser. Z. Naturforsch. 7b:148-155. |
| 23. | Yeung, R. S., J. M. Penninger, T. Kundig, W. Khoo, P. S. Ohashi, G. Kroemer, and T. W. Mak. 1996. Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock. Eur. J. Immunol. 26:1074-1082[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»